Anti-inflammatory cytokines and cytokine antagonists

被引:65
作者
Standiford, TJ [1 ]
机构
[1] Univ Michigan, Sch Med, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA
关键词
D O I
10.2174/1381612003400533
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytokines are critical mediators of protective host responses, including defense against microbial invasion and tumorigenesis. However, the production of specific proinflammatory cytokines must be tightly regulated and compartmentalized to prevent the overzealous expression of these molecules that can culminate in unabated inflammation and tissue injury. Cytokine production and/or biologic effects can be inhibited by a variety of endogenous molecules, including antiinflammatory cytokines, soluble cytokine receptors, and receptor antagonist proteins. Additionally, synthetic molecules have been constructed to selectively block the synthesis, post-translation processing, or receptor binding of proinflammatory cytokines. Relevant anti-inflammatory cytokines and cytokine inhibitors (both endogenous and synthetic) will be the subject of this review, with a particular emphasis on those anti-inflammatory cytokines and cytokine inhibitors that have been used experimentally or clinically in the treatment of diseases that are believed to be mediated by excessive proinflammatory cytokine responses.
引用
收藏
页码:633 / 649
页数:17
相关论文
共 146 条
[1]   EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[2]  
Abraham E, 1998, LANCET, V351, P929
[3]   p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial [J].
Abraham, E ;
Glauser, MP ;
Butler, T ;
Garbino, J ;
Gelmont, D ;
Laterre, PF ;
Kudsk, K ;
Bruining, HA ;
Otto, C ;
Tobin, E ;
Zwingelstein, C ;
Lesslauer, W ;
Leighton, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19) :1531-1538
[4]   IMMUNOSUPPRESSION INDUCED BY NITRIC-OXIDE AND ITS INHIBITION BY INTERLEUKIN-4 [J].
ALRAMADI, BK ;
MEISSLER, JJ ;
HUANG, D ;
EISENSTEIN, TK .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (09) :2249-2254
[5]   Imbalance of the interleukin 1 system in colonic mucosa - association with intestinal inflammation and interleukin 1 receptor agonist genotype 2 [J].
Andus, T ;
Daig, R ;
Vogl, D ;
Aschenbrenner, E ;
Lock, G ;
Hollerbach, S ;
Kollinger, M ;
Scholmerich, J ;
Gross, V .
GUT, 1997, 41 (05) :651-657
[6]   INTERLEUKIN-1 RECEPTOR ANTAGONIST [J].
AREND, WP .
ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 :167-227
[7]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[8]   INTRAARTICULAR EXPRESSION OF BIOLOGICALLY-ACTIVE INTERLEUKIN-1 RECEPTOR-ANTAGONIST PROTEIN BY EX-VIVO GENE-TRANSFER [J].
BANDARA, G ;
MUELLER, GM ;
GALEALAURI, J ;
TINDAL, MH ;
GEORGESCU, HI ;
SUCHANEK, MK ;
HUNG, GL ;
GLORIOSO, JC ;
ROBBINS, PD ;
EVANS, CH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (22) :10764-10768
[9]  
Baumhofer JM, 1998, EUR J IMMUNOL, V28, P610, DOI 10.1002/(SICI)1521-4141(199802)28:02<610::AID-IMMU610>3.3.CO
[10]  
2-X